The University of Nebraska Medical Center (UNMC) and ANANDA Scientific Inc. announced that the first patient has been enrolled in an FDA-approved clinical trial evaluating Nantheia ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure delivery technology, for post-traumatic stress disorder.
The trial is being led by principal investigator Matthew Rizzo, MD, FAAN, FANA, Frances & Edgar Reynolds chair, professor of the UNMC Department of Neurological Sciences, chief physician for neurological services at Nebraska Medicine, and chief physician for neurosciences clinical programs at Nebraska Medicine.
“We are very excited to have this important trial underway,” stated Dr. Rizzo. “Our collaboration with ANANDA Scientific is allowing us to advance evidence-based research into new therapeutics for the large PTSD patient population.”
Dr. Rizzo’s research team includes Jennifer Merickel, PhD, cognitive neuroscientist and assistant professor in the UNMC Department of Neurological Sciences, and Brigette Soltis-Vaughan, an advanced practice registered nurse, clinician and researcher in the UNMC Department of Psychiatry and instructor in the UNMC Department of Neurological Sciences.
“Enrolling the first patient in our second PTSD clinical trial is an important milestone for ANANDA’s clinical development program,” stated Sohail R. Zaidi, ANANDA’s CEO. “We are very pleased to be partnering with the UNMC’s research team in evaluating…